Breaking News

Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand NXC-201 Phase 1b/2 Clinical Trial

Recently reported Phase 1b clinical data from the ongoing clinical trial in Israel supports expanding the NXC-201 trial to the U.S.

Nexcella, Inc., a biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, has entered into a manufacturing agreement with a well-known United States Good Manufacturing Practice (GMP) cell therapy manufacturer that will supply a US Phase 1b/2 clinical trial of NXC-201 in relapsed/refractory multiple myeloma and AL amyloidosis. “We are excited about our progress toward bringing NXC-201 to United States clinical sites,” said ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters